Skip to main content
Erschienen in: Comparative Clinical Pathology 3/2011

01.06.2011 | Original Article

Alteration of some natural anticoagulants in dogs with chronic renal failure

verfasst von: Kreangsak Prihirunkit, Chalermpol Lekcharoensuk, Sunee Pooripanpipat, Saowanit Tipsawek

Erschienen in: Comparative Clinical Pathology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The diagnosis of hypercoagulation is essential for the identification of individuals at high risk for thrombosis and for early treatment of thrombotic disorder. The objective of the study was to evaluate some parameters for assessing the prothrombotic state in dogs with chronic renal failure (CRF). Some natural anticoagulants, protein C (PC), protein S (PS), and antithrombin III (AT III), as well as fibrinogen concentration and clinical chemistries, were concentrated. The study groups consisted of 42 dogs with CRF and 34 age- and sex-matched clinically healthy control dogs. The level of AT III in the CRF group was significantly lower (P < 0.05), but the fibrinogen concentration was significantly higher (P < 0.05) than in the control group. Additionally, the cholesterol level in the CRF group was significantly higher than in the control group (P < 0.05) and was positively correlated to creatinine (R = 0.5, P < 0.05). Elevated levels of PC and PS were exhibited in eight dogs with subcutaneous edema. The increased levels of PC and PS may counterbalance the reduction of AT III and may be related to the magnitude of hypoalbuminemia and proteinuria. These seem to be preventive mechanisms against thromboembolic phenomena. Simple correlations among parameters were determined for the CRF group. The fibrinogen concentration was correlated inversely with the AT III level (R = −0.63, P < 0.05). A negative correlation between AT III and azotemic parameters (creatinine: R = −0.68, P < 0.05; blood urea nitrogen (BUN): R = −0.65, P < 0.05) was observed also. In contrast, the fibrinogen concentration was positively correlated to creatinine (R = 0.66, P < 0.05) and BUN (R = 0.67, P < 0.05). The study concluded that there was a significant reduction in AT III and hyperfibrinogenemia, which were predictable parameters for thrombotic tendency in the dogs with CRF. Hypercholesterolemia was the other risk factor.
Literatur
Zurück zum Zitat Albella EM (1994) Hemostatic problems associated with renal disease. Int J Pediatr Hematol Oncol 1:43–51 Albella EM (1994) Hemostatic problems associated with renal disease. Int J Pediatr Hematol Oncol 1:43–51
Zurück zum Zitat Borgel D (1997) Protein S deficiency. Thromb Haemost 78:351–356PubMed Borgel D (1997) Protein S deficiency. Thromb Haemost 78:351–356PubMed
Zurück zum Zitat Citak A, Emre S, Sairin A, Bilge I, Nayir A (2000) Hemostatic problems and thromboembolic complications in nephritic children. Pediatr Nephrol 14:138–142PubMedCrossRef Citak A, Emre S, Sairin A, Bilge I, Nayir A (2000) Hemostatic problems and thromboembolic complications in nephritic children. Pediatr Nephrol 14:138–142PubMedCrossRef
Zurück zum Zitat Eberst E, Berkowitz LR (1994) Hemostasis in renal disease: pathophysiology and management. Am J Med 96:168–179PubMedCrossRef Eberst E, Berkowitz LR (1994) Hemostasis in renal disease: pathophysiology and management. Am J Med 96:168–179PubMedCrossRef
Zurück zum Zitat Erslev AJ, Besarab A (1997) Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 51:622–630PubMedCrossRef Erslev AJ, Besarab A (1997) Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 51:622–630PubMedCrossRef
Zurück zum Zitat Handeland GF, Abildgaard U, Aasen AO (1983) Simplified assay for antithrombin III activity using chromogenic peptide substrate. Scand J Haematol 31:427–436CrossRef Handeland GF, Abildgaard U, Aasen AO (1983) Simplified assay for antithrombin III activity using chromogenic peptide substrate. Scand J Haematol 31:427–436CrossRef
Zurück zum Zitat Hintze J (2007) NCSS, PASS and GESS. NCSS, Kaysville Hintze J (2007) NCSS, PASS and GESS. NCSS, Kaysville
Zurück zum Zitat Locatelli F, Vecchio LD, Manzoni C (1998) Morbidity and mortality on maintainance hemodialysis. Nephron 80:380–400PubMedCrossRef Locatelli F, Vecchio LD, Manzoni C (1998) Morbidity and mortality on maintainance hemodialysis. Nephron 80:380–400PubMedCrossRef
Zurück zum Zitat Lopez JA, Kearon C, Lee YYA (2004) Deep venous thrombosis. Hematology 1:439–456CrossRef Lopez JA, Kearon C, Lee YYA (2004) Deep venous thrombosis. Hematology 1:439–456CrossRef
Zurück zum Zitat NCCLS H30-A2 (2001) Procedure for the determination of fibrinogen in plasma: approved guideline, 2nd end. Wayne, Pensylvania NCCLS H30-A2 (2001) Procedure for the determination of fibrinogen in plasma: approved guideline, 2nd end. Wayne, Pensylvania
Zurück zum Zitat Özkaya O, Bek K, Fisgin T et al (2006) Low protein Z levels in children with nephritic syndrome. Pediatr Nephrol 21:1122–1126PubMedCrossRef Özkaya O, Bek K, Fisgin T et al (2006) Low protein Z levels in children with nephritic syndrome. Pediatr Nephrol 21:1122–1126PubMedCrossRef
Zurück zum Zitat Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ (1994) Thrombosis and hemostasis in renal disease. Kidney Int 46:287–296PubMedCrossRef Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ (1994) Thrombosis and hemostasis in renal disease. Kidney Int 46:287–296PubMedCrossRef
Zurück zum Zitat Salvatierra A, Guerrero R, Rodriquez M et al (2001) Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dogs. Circulation 104:2975–2980PubMedCrossRef Salvatierra A, Guerrero R, Rodriquez M et al (2001) Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dogs. Circulation 104:2975–2980PubMedCrossRef
Zurück zum Zitat Singhal R, Brimble KS (2006) Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thrombo Res 118:397–407CrossRef Singhal R, Brimble KS (2006) Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thrombo Res 118:397–407CrossRef
Zurück zum Zitat Sturk A, Morrien-Salomons WM, Huisman MV et al (1987) Analytical and clinical evaluation of commercial protein C assays. Clin Chim Acta 165:263–270PubMedCrossRef Sturk A, Morrien-Salomons WM, Huisman MV et al (1987) Analytical and clinical evaluation of commercial protein C assays. Clin Chim Acta 165:263–270PubMedCrossRef
Zurück zum Zitat Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:262–272CrossRef Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:262–272CrossRef
Metadaten
Titel
Alteration of some natural anticoagulants in dogs with chronic renal failure
verfasst von
Kreangsak Prihirunkit
Chalermpol Lekcharoensuk
Sunee Pooripanpipat
Saowanit Tipsawek
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Comparative Clinical Pathology / Ausgabe 3/2011
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-010-0981-x

Weitere Artikel der Ausgabe 3/2011

Comparative Clinical Pathology 3/2011 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …